

June 2, 2020

BSE Limited

Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001

Scrip code: 532531

Dear Madam/ Sir,

Subject: Press Release

Please find attached Press Release issued by the Company titled:

"Strides receives USFDA approval for Triamcinolone Acetonide Ointment"

The National Stock Exchange of India Limited

Exchange Plaza, Bandra-Kurla Complex

Bandra (E) Mumbai - 400 051

Scrip code: STAR

Thanking you,

Yours faithfully,

For Strides Pharma Science Limited

Manjula Ramamurthy Company Secretary

Menjula S.

Encl. As above



(Formerly Strides Shasun Limited) CIN: L24230MH1990PLC057062



Strides receives USFDA approval for Triamcinolone Acetonide Ointment

Product approval from flagship facility in Bangalore To be marketed by Strides Pharma Inc. in the US market

Bangalore, June 02, 2020 - Strides Pharma Science Limited (Strides) today announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for *Triamcinolone Acetonide Ointment USP*, 0.05% from the United States Food & Drug Administration (USFDA). The product is part of the niche and small volume product portfolio with limited competition in the US market.

According to IQVIA MAT data, the US market for Triamcinolone Acetonide Ointment USP, 0.05% is approximately US\$ 15 Mn. The product will be manufactured at the company's flagship facility at Bangalore and will be marketed by Strides Pharma Inc. in the US market.

The company has 124 cumulative ANDA filings with USFDA of which 86 ANDAs have been approved and 38 are pending approval.

About Triamcinolone Acetonide Ointment

Triamcinolone Acetonide Ointment 0.05% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.

About Strides

Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India. The Company mainly operates in the regulated markets and has an "in Africa for Africa" strategy along with an institutional business to service donor-funded markets. The Company's global manufacturing sites are located in India- Bangalore (two locations), Pondicherry, and Chennai, Singapore, Italy- Milan, Kenya- Nairobi and United States-Florida. The Company focusses on "difficult to manufacture" products that are sold in over 100 countries. Additional information is available at the Company's website at www.strides.com

For further information, please contact:

Strides

Badree Komandur

Executive Director - Finance +91 80 6784 0747

Investor Relations:

Sandeep Baid: +91 80 6784 0791

PR Consultancy

Fortuna PR

K Srinivas Reddy: +91 90005 27213

srinivas@fortunapr.com

K Priya: +91 95354 25418 priya@fortunapr.com

Kannan. N: +91 98450 54745

Email: Sandeep.baid@strides.com

Strides Pharma Science Limited

(Formerly Strides Shasun Limited)

CIN: L24230MH1990PLC057062

Regd. Office: 201, 'Devavrata', Sector - 17,

Vashi, Navi Mumbai - 400 703

Corp. Office: Strides House, Bannerghatta

Road, Bangalore – 560 076